General Resources / Legal Resources / Medical
Resources / Briefing Papers / State Activity
Hospital Closures / Preventable
Tragedies / Press Room / Search
Our Site / Home
PRESS RELEASE
FOR
IMMEDIATE RELEASE: August 31, 2007 |
Contact: Alicia Aebersold at 703 294 6008 or [email protected] Stacy Fiedler at 703-294-6003 or [email protected] |
ARLINGTON, VA – What happened to keep Seung Hui Cho from getting needed treatment and at what point could the Virginia Tech massacre have been prevented? The state-appointed panel charged with answering those questions released its report today, stating in part that “The Virginia standard for involuntary commitment is one of the most restrictive in the nation and is not uniformly applied.”
The report details the many lost opportunities to help Cho and makes recommendations to improve Virginia’s restrictive mental health treatment law.
“Gov. Kaine and the independent panel should be commended for not only identifying many of the flaws in the system that prevented Cho from getting treatment,” said John Snook, “but for recognizing the critical importance of a strong assisted outpatient treatment program that will allow humane intervention before tragedy strikes.” Snook is the legislative and policy counsel for the Treatment Advocacy Center, a national nonprofit dedicated to removing barriers to timely and effective treatment of severe mental illnesses.
“It now falls on the legislature to act to improve state law,” said Snook. “Families across Virginia are struggling to help their loved ones. There is no question people who are clearly psychotic should get treatment. But Virginia needs to do better than that, as the Governor’s panel recommends, and help people before they become a danger.”
The Treatment Advocacy Center (www.treatmentadvocacycenter.org) is a national nonprofit organization dedicated to eliminating barriers to the timely and effective treatment of severe mental illnesses. TAC promotes laws, policies, and practices for the delivery of psychiatric care and supports the development of innovative treatments for and research into the causes of severe and persistent psychiatric illnesses, such as schizophrenia and bipolar disorder.
We take no money from pharmaceutical companies. The American Psychiatric Association awarded TAC its 2006 presidential commendation for "sustained extraordinary advocacy on behalf of the most vulnerable mentally ill patients.”
ADDITIONAL INFORMATION
press room
general
resources | legal resources | medical
resources | briefing papers | state activity
hospital closures | preventable
tragedies | press room | search
| home
The contents of TAC's website are copyrighted by the Treatment Advocacy Center unless otherwise indicated. All rights reserved and content may be reproduced, downloaded, disseminated, or transferred, for single use, or by nonprofit organizations for educational purposes only, if correct attribution is made. TAC is an I.R.C. � 501(c)(3) tax-exempt corporation. Donations are appreciated and are eligible for the charitable contribution deduction under the provisions of I.R.C. � 170. Please note that TAC does not accept funding from pharmaceutical companies or entities involved in the sale, marketing, or distribution of such products. Treatment Advocacy Center (TAC), 200 N. Glebe Road, Suite 730, Arlington, VA 22203 703 294 6001/6002 (phone) | 703 294 6010 (fax) | www.treatmentadvocacycenter.org (website) [email protected] (general email) | [email protected] (press contact) [email protected] (webmaster) |